119 related articles for article (PubMed ID: 7697545)
1. Construction of a functional disulfide-stabilized TCR Fv indicates that antibody and TCR Fv frameworks are very similar in structure.
Reiter Y; Kurucz I; Brinkmann U; Jung SH; Lee B; Segal DM; Pastan I
Immunity; 1995 Mar; 2(3):281-7. PubMed ID: 7697545
[TBL] [Abstract][Full Text] [Related]
2. Engineering interchain disulfide bonds into conserved framework regions of Fv fragments: improved biochemical characteristics of recombinant immunotoxins containing disulfide-stabilized Fv.
Reiter Y; Brinkmann U; Webber KO; Jung SH; Lee B; Pastan I
Protein Eng; 1994 May; 7(5):697-704. PubMed ID: 8073039
[TBL] [Abstract][Full Text] [Related]
3. Disulfide stabilization of antibody Fv: computer predictions and experimental evaluation.
Reiter Y; Brinkmann U; Jung SH; Pastan I; Lee B
Protein Eng; 1995 Dec; 8(12):1323-31. PubMed ID: 8869646
[TBL] [Abstract][Full Text] [Related]
4. Engineering antibody Fv fragments for cancer detection and therapy: disulfide-stabilized Fv fragments.
Reiter Y; Brinkmann U; Lee B; Pastan I
Nat Biotechnol; 1996 Oct; 14(10):1239-45. PubMed ID: 9631086
[TBL] [Abstract][Full Text] [Related]
5. Antitumor activity and pharmacokinetics in mice of a recombinant immunotoxin containing a disulfide-stabilized Fv fragment.
Reiter Y; Pai LH; Brinkmann U; Wang QC; Pastan I
Cancer Res; 1994 May; 54(10):2714-8. PubMed ID: 8168102
[TBL] [Abstract][Full Text] [Related]
6. Cytotoxic and antitumor activity of a recombinant immunotoxin composed of disulfide-stabilized anti-Tac Fv fragment and truncated Pseudomonas exotoxin.
Reiter Y; Kreitman RJ; Brinkmann U; Pastan I
Int J Cancer; 1994 Jul; 58(1):142-9. PubMed ID: 8014011
[TBL] [Abstract][Full Text] [Related]
7. A recombinant immunotoxin containing a disulfide-stabilized Fv fragment.
Brinkmann U; Reiter Y; Jung SH; Lee B; Pastan I
Proc Natl Acad Sci U S A; 1993 Aug; 90(16):7538-42. PubMed ID: 8356052
[TBL] [Abstract][Full Text] [Related]
8. Phage display of disulfide-stabilized Fv fragments.
Brinkmann U; Chowdhury PS; Roscoe DM; Pastan I
J Immunol Methods; 1995 May; 182(1):41-50. PubMed ID: 7769243
[TBL] [Abstract][Full Text] [Related]
9. Stabilization of the Fv fragments in recombinant immunotoxins by disulfide bonds engineered into conserved framework regions.
Reiter Y; Brinkmann U; Kreitman RJ; Jung SH; Lee B; Pastan I
Biochemistry; 1994 May; 33(18):5451-9. PubMed ID: 7910034
[TBL] [Abstract][Full Text] [Related]
10. Design of interchain disulfide bonds in the framework region of the Fv fragment of the monoclonal antibody B3.
Jung SH; Pastan I; Lee B
Proteins; 1994 May; 19(1):35-47. PubMed ID: 8066084
[TBL] [Abstract][Full Text] [Related]
11. Improved binding and antitumor activity of a recombinant anti-erbB2 immunotoxin by disulfide stabilization of the Fv fragment.
Reiter Y; Brinkmann U; Jung SH; Lee B; Kasprzyk PG; King CR; Pastan I
J Biol Chem; 1994 Jul; 269(28):18327-31. PubMed ID: 7913461
[TBL] [Abstract][Full Text] [Related]
12. Antibody engineering of recombinant Fv immunotoxins for improved targeting of cancer: disulfide-stabilized Fv immunotoxins.
Reiter Y; Pastan I
Clin Cancer Res; 1996 Feb; 2(2):245-52. PubMed ID: 9816166
[TBL] [Abstract][Full Text] [Related]
13. Identification of residues that stabilize the single-chain Fv of monoclonal antibodies B3.
Benhar I; Pastan I
J Biol Chem; 1995 Oct; 270(40):23373-80. PubMed ID: 7559495
[TBL] [Abstract][Full Text] [Related]
14. The disulfide bonds in antibody variable domains: effects on stability, folding in vitro, and functional expression in Escherichia coli.
Glockshuber R; Schmidt T; Plückthun A
Biochemistry; 1992 Feb; 31(5):1270-9. PubMed ID: 1736986
[TBL] [Abstract][Full Text] [Related]
15. Recombinant immunotoxin containing a disulfide-stabilized Fv directed at erbB2 that does not require proteolytic activation.
Kuan CT; Pastan I
Biochemistry; 1996 Mar; 35(9):2872-7. PubMed ID: 8608123
[TBL] [Abstract][Full Text] [Related]
16. A form of anti-Tac(Fv) which is both single-chain and disulfide stabilized: comparison with its single-chain and disulfide-stabilized homologs.
Rajagopal V; Pastan I; Kreitman RJ
Protein Eng; 1997 Dec; 10(12):1453-9. PubMed ID: 9543007
[TBL] [Abstract][Full Text] [Related]
17. Vl-linker-Vh orientation-dependent expression of single chain Fv-containing an engineered disulfide-stabilized bond in the framework regions.
Luo D; Mah N; Krantz M; Wilde K; Wishart D; Zhang Y; Jacobs F; Martin L
J Biochem; 1995 Oct; 118(4):825-31. PubMed ID: 8576099
[TBL] [Abstract][Full Text] [Related]
18. Similarities in the biodistribution of iodine-labeled anti-Tac single-chain disulfide-stabilized Fv fragment and anti-Tac disulfide-stabilized Fv fragment.
Kobayashi H; Han ES; Kim IS; Le N; Rajagopal V; Kreitman RJ; Pastan I; Paik CH; Carrasquillo JA
Nucl Med Biol; 1998 May; 25(4):387-93. PubMed ID: 9639301
[TBL] [Abstract][Full Text] [Related]
19. Rapid humanization of the Fv of monoclonal antibody B3 by using framework exchange of the recombinant immunotoxin B3(Fv)-PE38.
Benhar I; Padlan EA; Jung SH; Lee B; Pastan I
Proc Natl Acad Sci U S A; 1994 Dec; 91(25):12051-5. PubMed ID: 7991583
[TBL] [Abstract][Full Text] [Related]
20. A bivalent disulfide-stabilized Fv with improved antigen binding to erbB2.
Bera TK; Onda M; Brinkmann U; Pastan I
J Mol Biol; 1998 Aug; 281(3):475-83. PubMed ID: 9698563
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]